ORLANDO, Fla. Nov 17 An experimental drug for
patients genetically disposed to extreme high cholesterol being
developed by Isis Pharmaceuticals Inc ISIS.O and Genzyme
CorpGENZ.O significantly lowered cholesterol in a pivotal
late-stage study, according to data presented on Tuesday.
The drug, mipomersen, succeeded in attaining the main goal
of the trial, cutting "bad" LDL cholesterol by 25 percent
compared with just a 3 percent reduction from placebo in
patients with a very rare condition known as homozygous
Genzyme, which will market the drug under a deal with Isis,
plans to apply for U.S. and European approval by mid-2011.
People with the condition, which is inherited from both
parents, tend to have cholesterol at four times normal levels
and are at extreme high risk of heart attack and early death.
Mipomersen also succeeded in all the secondary and tertiary
goals of the trial by cutting levels of other dangerous
particles, suggesting the drug may offer benefits to patients
beyond LDL reduction, researchers said.
(Reporting by Bill Berkrot and Ransdell Pierson, editing by
Gerald E. McCormick)